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Abstract
Purpose: To assess the differences in the frequency of clinical signs of temporoman-
dibular disorder (TMD) pain and mandibular function impairment between mandibu-
lar advancement device (MAD) and nasal continuous positive airway pressure
(nCPAP) therapies in obstructive sleep apnea (OSA) patients at baseline and after
6 month of treatment.
Methods: This study concerns a secondary analysis of a randomized placebo-
controlled trial in which different treatment effects of an objectively titrated MAD
were compared with those of nCPAP and an intra-oral placebo appliance in a parallel
design. Sixty-four mild to severe OSA patients (52.0 ± 9.6 years) were randomly
assigned to these three groups. All patients underwent a shortened functional exami-
nation of their masticatory system at baseline and after 6 months to establish the
presence of clinical signs of TMD pain. Mandibular function impairment was assessed
with a questionnaire.
Results: Clinical signs of TMD pain were only rarely present at baseline and therapy
evaluation. No significant differences were found between the three groups in the
(low) frequency of clinical signs of TMD pain at both time points (p = .401–.176). In
addition, the (low) scores of mandibular function impairment did not differ between
the three groups either, neither at baseline (p = .744) nor after 6 months (p = .359).
Conclusions: A low frequency of clinical signs of TMD pain in mild to severe OSA
patients was found after 6 months, regardless of treatment with MAD or nCPAP. In
addition, no difference in mandibular function impairment was observed between
the different treatment modalities.
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1 | INTRODUCTION
Obstructive sleep apnea (OSA) is characterized by recurrent obstruc-
tions of the upper airway, often resulting in oxygen desaturations and
arousals from sleep (American Academy of Sleep Medicine, 1999). OSA
is a common sleep-related breathing disorder that affects 10–17% of
middle-aged men and 3–9% of middle-aged women, with a higher prev-
alence amongst obese patients (Badran, Ayas, & Laher, 2014). OSA
patients without effective treatment have an increased risk of cardio-
vascular conditions like hypertension, stroke, heart failure, and atrial
fibrillation (Ayas, Owens, & Kheirandish-Gozal, 2015; Marin, Carrizo,
Vicente, & Agusti, 2005; Yaggi et al., 2005).
The treatment of OSA has been undergoing a steady shift over
the last years. While (nasal) CPAP ([n]CPAP) was more or less the sole
effective treatment for many years, mandibular advancement device
(MAD) therapy is increasingly recognized as a viable treatment for
OSA (Aarab, Lobbezoo, Hamburger, & Naeije, 2011; Ramar
et al., 2015). MADs are currently indicated for the treatment of mild
to moderate OSA patients as well as of severe OSA patients who are
intolerant to or refuse CPAP therapy (Aarab, Lobbezoo, Hamburger, &
Naeije, 2011; Ramar et al., 2015). MADs protrude the mandible and
improve upper airway patency by enlarging the upper airway and/or
by reducing its collapsibility (Schmidt-Nowara et al., 1995). During the
monitoring phase of this treatment, the mandibular protrusion posi-
tion of the MAD is often titrated by the dentist or patient to improve
its efficacy and to reduce its side-effects (Aarab, Lobbezoo, Ham-
burger, & Naeije, 2010). However, due to their design, MADs exert
potentially detrimental forces on the teeth, oral soft tissues, and mus-
culoskeletal structures of the masticatory system. Amongst others,
MADs may result in excessive salivation, mouth dryness, and tempo-
romandibular side-effects in the short-term (Doff et al., 2012; Ham-
mond et al., 2007; Martinez-Gomis et al., 2010; Pantin, Hillman, &
Tennant, 1999; Tegelberg et al., 1999).
Temporomandibular disorders (TMDs) are defined as musculo-
skeletal disorders that include symptoms like pain and dysfunction of
the temporomandibular joint and/or the jaw muscles (de Leeuw &
Klasser, 2018). De Leeuw and Klasser (2018) extensively describe var-
ious methods for the clinical assessment of TMD pain, all of them
based on a combination of self-report and clinical tests that provoke
the musculoskeletal system. Importantly, the clinical assessment of
the impairment of mandibular function associated with TMDs should
not only comprise a diagnostic assessment of symptoms and signs but
also an assessment of the functional impairment as it is perceived in
the patient's value system (Stegenga, de Bont, de Leeuw, &
Boering, 1993).
Both improvements and deteriorations in signs and symptoms of
TMDs have been found during MAD treatment (Bondemark &
Lindman, 2000; Cunali et al., 2009; Doff et al., 2012; Fransson,
Tegelberg, Leissner, Wenneberg, & Isacsson, 2003; Giannasi
et al., 2009; Martinez-Gomis et al., 2010; Petit et al., 2002). Most pre-
vious studies, however, were retrospective in design or did not
include a placebo group (Bondemark & Lindman, 2000; Cunali
et al., 2009; Doff et al., 2012; Martinez-Gomis et al., 2010). Moreover,
the impact of the TMD on the patient's mandibular function has sel-
dom been determined (Doff et al., 2012). Therefore, a definitive con-
clusion about the frequency of TMD side-effects and their impact on
mandibular function in OSA patients under MAD treatment cannot be
drawn.
The aim of this study was to assess the differences in the fre-
quency of clinical signs of TMD pain and in the mandibular function
impairment between MAD and nCPAP therapies at baseline and after
6 months in mild to severe OSA patients in a randomized, placebo-
controlled trial design. We hypothesized that an MAD would result in
significantly more clinical signs of TMD pain than nCPAP and placebo.
Further, this TMD pain was hypothesized to lead to more mandibular
function impairment in the MAD group than in the nCPAP and pla-
cebo groups.
2 | MATERIALS AND METHODS
This study concerns a secondary analysis of a large randomized
placebo-controlled trial in which different treatment effects of an
objectively titrated MAD were compared with those of nCPAP and an
intra-oral placebo appliance in a parallel design. The short-term and
long-term outcomes of this trial have been published previously
(Aarab et al., 2010; Aarab, Lobbezoo, Hamburger, & Naeije, 2011;
Aarab, Lobbezoo, Heijmans, Hamburger, & Naeije, 2011).
2.1 | Participants
Potential participants were recruited from the Center for Sleep–Wake
Disorders of the Slotervaart Medical Center in Amsterdam, The Neth-
erlands. The multidisciplinary team of this center consisted of a neu-
rologist, ENT specialists, pulmonologists, a dentist, psychologists, and
sleep medicine technicians. All participants were at least 18 years old,
with an apnea-hypopnea index (AHI) of 5–45 events/hr. They all
reported excessive daytime sleepiness (Epworth sleepiness scor-
e ≥ 10), or at least two OSA symptoms presented by the American
Academy of Sleep Medicine Task Force (e.g., daytime sleepiness,
fatigue) (American Academy of Sleep Medicine, 1999). The exclusion
criteria were the existence of sleep disorders other than OSA based
on polysomnography, a body mass index (BMI) of more than 40, usage
of medication that affects sleep or respiration, reversible morphologi-
cal upper airway abnormalities, and previous treatment with nCPAP
or an intraoral appliance. Patients with clinical signs of temporoman-
dibular disorders (TMDs; diagnosis based on a functional examination
of the masticatory system; Visscher et al., 2009) who also expressed a
desire for treatment of their TMD complaints, an unhealthy per-
iodontium (periodontal pockets >5 mm), dental pain, and/or an inade-
quate retention possibilities for an intra-oral appliance were excluded
as well. Two-hundred-nineteen participants were eligible for the
study. Seventy-three of them did not meet the medical inclusion
criteria, and 29 patients did not meet the dental inclusion criteria.
Thirty-one patients refused to participate and 22 patients did not
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participate for other reasons, for example, loss of contact. Finally, a
total of 64 OSA patients agreed to participate and provided written
informed consent (Figure 1). The scientific and ethical aspects of the
protocol were reviewed and approved by the Medical Ethics Commit-
tee of the Slotervaart Medical Center (## U/1731/0326,
U/2679/0326). This study has been registered at www.clinicaltrials.
gov (# NCT00950495).
2.2 | Interventions
The nCPAP group used the REMstar Pro system (Respironics,
Herrsching, Germany). The MAD group used a custom-made device
with an individually adjustable mandibular protrusion position at a
constant vertical dimension, the design of which has been described
in detail previously (Aarab et al., 2010). The MAD did not allow verti-
cal opening and lateral movements. The placebo group used a thin
(<1 mm) hard acrylic resin palatal splint with only a partial coverage of
the hard palate and no interference with the dental occlusion (Aarab,
Lobbezoo, Hamburger, & Naeije, 2011).
2.3 | Study protocol
The protocol of this study has been described in detail previously
(Aarab, Lobbezoo, Hamburger, & Naeije, 2011). Below, an outline is
provided with the protocol's key characteristics, along with pertinent
additions that made it possible to answer the current research
question.
All patients were randomly allocated to one of the three therapy
groups. To ensure that the groups were of approximately the same
size, block randomization was used. Block sizes were 6, 12, and 18;
sizes were randomly varied. The allocation sequence was automati-
cally generated and subsequently concealed by an independent co-
F IGURE 1 Flow-chart of the patients through each stage of the trial. MAD, mandibular advancement device; nCPAP, nasal continuous
positive airway pressure; OSA, obstructive sleep apnea
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worker, who kept a paper copy in a lockable drawer. Sealed opaque
envelopes were used to conceal the allocation from the principal
investigator (Aarab, Lobbezoo, Hamburger, & Naeije, 2011). Both
MAD and nCPAP were titrated before the start of the treatment
(Aarab, Lobbezoo, Hamburger, & Naeije, 2011). For the titration of
the MAD, four ambulatory polysomnographic (PSG) recordings were
performed at regular time intervals of approximately 3 weeks. The
total titration period was approximately 10 weeks. The most effective
protrusion position of the MAD (i.e., the mandibular position that
yielded the lowest AHI value) was chosen from among four randomly
offered positions, namely, 0, 25, 50, and 75% of the maximum protru-
sion. The MAD was set at 25% of the maximum protrusion in one
patient, at 50% in 7 patients, and 75% in 12 patients (Aarab,
Lobbezoo, Hamburger, & Naeije, 2011). The titration of nCPAP was
performed during a PSG recording at the Slotervaart Medical Center.
The pressure was increased in steps of 1 cm H2O/hr, until the AHI
and respiration-related arousals were reduced to ≤5 events/hr, and
snoring was minimized. The average value of the pressure was 7.3
(SD, 1.9; range, 4–11) cm H2O (Aarab, Lobbezoo, Hamburger, &
Naeije, 2011). For the placebo group, four ambulatory PSG recordings
were performed at regular time intervals similar to the MAD group
(Aarab, Lobbezoo, Hamburger, & Naeije, 2011).
During the titration period of approximately 10 weeks, all
patients visited ACTA four times at regular intervals, during which the
BMI (kg/m2) was determined and the Epworth Sleepiness Scale (ESS)
was completed (Johns, 1991). The participants were also interviewed
about their compliance (% of nights per week of wearing), and the
change (increased, unchanged, or decreased) in snoring intensity,
based on information they obtained from their bed partner. These
outcomes have been described in detail by Aarab, Lobbezoo, Ham-
burger, and Naeije (2011). Further, the visits at ACTA were also used
to adjust the protrusion position of the MAD according to the random
order of the study protocol.
Besides the above-described titration PSGs, all three groups
underwent two full PSG recordings in the sleep laboratory of the
Slotervaart Medical Center: The first one before treatment and the
second one 6.0 ± 2.0 months (mean ± SD) after the start of the treat-
ment. The outcomes of the PSG recordings have been published by
Aarab et al. (2011).
2.4 | Clinical signs of TMD pain and mandibular
function impairment
During the consultations at baseline and after 6 months of treatment,
patients were informed about the mild and transient nature of a possi-
ble TMD pain by the clinician. The assessment of TMD pain and man-
dibular function impairment was performed at both time points. The
assessment included, amongst others, an oral history and orthopedic
tests, namely, the static and dynamic tests (Visscher et al., 2009). A
single, experienced, and well-trained clinician performed all examina-
tions throughout the entire study. This clinician was not blinded for
the type of treatment of each patient. Clinical signs of TMD pain was
considered present when patients reported pain on at least one of the
static or dynamic tests during opening, closing, and protrusion of the
mandible. The presence of clinical signs of TMD pain was scored “1”,
and their absence was scored “0”.
The Mandibular Function Impairment Questionnaire (MFIQ) was
completed by all patients at baseline and after 6 months, to subjec-
tively assess function impairment of the masticatory system. The
MFIQ is a validated questionnaire, which is used to assess the impact
of TMDs on mandibular function in daily life (Stegenga et al., 1993).
The MFIQ scores perceived difficulty of 17 representative mandibular
functions in relation to joint or muscle complaints. The answers are
scored on five-point Likert-type scales (0–4), where 0 represents “no
difficulty” and 4 represents “very great difficulty or impossible without
help”. The sum item score for function impairment ranges from 0 to
68. Using these scores, a Raw Component Score is calculated and a
functional impairment rating scale (FIRS) is derived (0–5). A FIRS of
0 or 1 indicates low level of function impairment, a FIRS of 2 or 3 indi-
cates moderate level of function impairment, and a FIRS of 4 or 5 indi-
cates severe level of function impairment.
2.5 | Statistical analysis
The null hypothesis of this study was that there is no significant dif-
ference between the MAD group, the nCPAP group, and the placebo
group in the presence of clinical signs of TMD pain at baseline and at
therapy evaluation. The chi-square (X2) test was used to examine
whether the distributions of TMD pain between the three groups dif-
fered. The Wilcoxon Signed rank test (for the within groups compari-
son) and the Kruskal–Wallis tests (for the between-groups
comparison) were used to test the difference between the three
groups in the change of their FIRS score between baseline and
6 months after the start of the treatment. All statistical analyses were
performed using the Statistical Package for the Social Sciences (ver-
sion 24.0, SPSS Inc., Chicago, IL). p < .05 was considered statistically
significant.
3 | RESULTS
The patient characteristics at baseline are presented in Table 1. BMI
was the only baseline characteristic that differed between the three
therapy groups. Seven patients dropped out of the study for various
reasons (Figure 1). Thus, 57 participants (20 MAD patients, 18 nCPAP
patients, and 19 placebo patients) completed the entire study protocol
(Aarab, Lobbezoo, Hamburger, & Naeije, 2011).
Details of the primary analyses of the RCT have been described
previously; see (Aarab, Lobbezoo, Hamburger, & Naeije, 2011). In
short, the MAD group had used their appliance 90.6% (SD, 13.3) of
the nights; the nCPAP group 82.9% (SD, 27.2) of the nights; and the
placebo group 93.9% (SD, 15.7) of the nights. No significant group dif-
ferences in compliance were found (F = 1.518, p = .228). In addition,
BMI did not change significantly from baseline to 6-month follow-up
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in any of the three therapy groups (paired t tests; p = .408–.752). AHI,
on the other hand, showed a significant improvement over time in all
three therapy groups. The decrease in AHI from baseline to 6-month
follow-up differed significantly between the groups (ANCOVA;
F = 14.886, p = .000). While this decrease was comparable for MAD
and nCPAP (p = .092), both treatments showed a significantly larger
decrease than the placebo condition (p = .000 and .0002, respec-
tively). Finally, for excessive daytime sleepiness, the pooled data of
the three groups showed a significant decrease over time (paired
t test, p = .002).
In Table 2, the outcome variables are presented. Clinical signs of
TMD pain were only rarely encountered. No significant differences
were found between the three treatment groups in the (low) fre-
quency of the clinical signs of TMD pain at baseline and at therapy
evaluation after 6 months (χ2 = 1.830 and χ2 = 3.478; p = .401 and
.176, respectively). All FIRS scores were qualified as low. There was
no significant change in the FIRS score within the groups between
baseline and therapy evaluation (Z = −0.632; p = .527), nor was there
a significant difference between the three different treatment groups
in their (low) level of mandibular function impairment at baseline
(p = .744) and after 6 months (p = .359; Table 2).
4 | DISCUSSION
The aim of this study was to assess the differences in the frequency of
clinical signs of TMD pain and mandibular function impairment after
6 months of treatment between MAD and nCPAP therapies in mild to
severe OSA patients in a randomized, placebo-controlled trial design.
No significant differences were found between the three treatment
groups in the frequency of clinical signs of TMD pain at baseline and at
therapy evaluation after 6 months. Further, there was no significant dif-
ference between the three different treatment groups in their (low)
level of mandibular function impairment in daily life either.
A study of Sanders et al. (2013) tested the hypothesis that signs
and symptoms of OSA are associated with the occurrence of TMD,
and precede first-onset TMD. Their data was based on a prospective
study (n = 2,604) and a case–control study (n = 1,716). Both studies
supported a significant association between OSA symptoms and
TMD, and they found evidence that OSA symptoms preceded first-
onset TMD. One of their explanations for OSA preceding TMD was
that OSA patient shows more sleep bruxism (SB) activity and there-
fore more TMD. However, there is no solid evidence for the cause–
effect relationship between OSA and SB on one hand, and between
SB and TMD on the other hand (Manfredini, Guarda-Nardini,
Marchese-Ragona, & Lobbezoo, 2015; Manfredini & Lobbezoo, 2010).
Furthermore, OSA was not determined objectively (i.e., by means of
PSG) in the study of Sanders et al. (2013). Therefore, their hypothesis
should be tested further in future studies. Nevertheless, Kato
et al. (2013) found self-reported jaw symptoms (viz., morning jaw dis-
comfort, morning jaw pain, daytime jaw pain, and jaw opening difficul-
ties) in 19% of 511 OSA patients. Further, Perez et al. (2013) showed
that TMD pain was present in approximately 10% of their OSA
patients at baseline, based on a clinical examination, which corre-
sponds with the TMD-pain prevalence rate of 10% in the general pop-
ulation (LeResche, 1997). Based on these studies, we may conclude
that TMD is associated with OSA. However, TMD pain may be equally
prevalent in OSA patients and the general population.
TABLE 1 Patient characteristics (mean ± SD) at baseline of the mandibular advancement device (MAD) group, the nasal continuous positive
airway pressure (nCPAP) group, the placebo group, and the dropouts; see (Aarab, Lobbezoo, Hamburger, & Naeije, 2011) for more details
MAD (N = 21) nCPAP (N = 22) Placebo (N = 21) Dropouts (N = 7)
Age (years) 50.4 ± 8.9 54.0 ± 10.1 51.3 ± 9.6 49.3 ± 7.3
Number of men/women 17/4 15/7 15/6 5/2
Apnea-hypopnea index (AHI) 21.4 ± 11.0 20.1 ± 9.0 19.5 ± 8.4 14.8 ± 3.8
Epworth sleepiness scale 12.0 ± 5.7 10.7 ± 4.4 10.8 ± 4.0 13.7 ± 1.9
Body mass Indexa (kg/m2) 27.1 ± 3.2 30.7 ± 3.7 31.1 ± 4.7 27.8 ± 4.1
aMAD patients had a significantly lower BMI than placebo and nCPAP patients (p = .002 and .006, respectively; one-way ANOVA, followed by
least-significant difference pairwise comparisons).
TABLE 2 Presence of clinical signs of TMD pain and the Function Impairment Rating Scale (FIRS) score at baseline and 6 months after the
start of the therapy for the mandibular advancement device (MAD) group, the nasal continuous positive airway pressure (nCPAP) group, and the
placebo group
Outcome measures
MAD (n = 20) nCPAP (n = 18) Placebo (n = 19)
Baseline 6 months Baseline 6 months Baseline 6 months
Presence of clinical signs of TMD pain (n)a 0 0 2 2 1 0
FIRS score (25%|median|75%)b 0|0|1 0|0|0.50 0|0|0.25 0|0|1 0|0|0 0|0|0
aNumber of complete data sets per group: MAD (n = 18); nCPAP (n = 17); placebo (n = 14).
bNumber of complete data sets per group: MAD (n = 17); nCPAP (n = 13); placebo (n = 18).
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The present study concerns a secondary analysis of a large ran-
domized placebo-controlled trial, the short-term and long-term out-
comes of which have been published previously (Aarab et al., 2010;
Aarab, Lobbezoo, Hamburger, & Naeije, 2011; Aarab, Lobbezoo,
Heijmans, et al., 2011). This means that the data that were analyzed
to answer the present research questions were originally collected for
other purposes. While the advantages of using secondary data are
clear (e.g., time-saving, cost-efficient), its use is also associated with
potential disadvantages, such as the application outdated or inaccu-
rate methods that may jeopardize the validity of the results. In the
present study, however, both TMD pain and mandibular function
impairment were assessed with up-to-date and validated tools,
namely, static and dynamic tests (Visscher et al., 2009) and Mandibu-
lar Function Impairment Questionnaire (Stegenga et al., 1993), respec-
tively. Hence, we are confident that in the present study, the use of
secondary data has yielded accurate outcomes.
The experienced and well-trained clinician who performed all
examinations throughout the entire study was not blinded for the
type of treatment of each patient. Since this approach is associated
with a risk of observer bias, this could be considered as a potential
limitation of the present study. Further, not all patients completed the
entire protocol of the present study. Therefore, both our original
study sample and the dropouts contributed to a reduced power of this
study. Missing values may lead to selection bias, because participants
who complete the entire study may show better treatment outcomes
than dropouts (Donders, van der Heijden, Stijnen, & Moons, 2006).
However, the outcomes of our study are similar to previous ones.
Perez et al. (2013)determined the prevalence and incidence of TMD
pain in 167 OSA patients undergoing MAD treatment. They found
that after approx. 4 months, TMD pain was present in only a small
proportion of their study sample and that this pain was no longer pre-
sent after 1 year. Similar findings were reported by Doff et al. in their
study wherein 51 MAD patients were compared to 52 CPAP patients
on the occurrence of TMD and the risk of pain and function impair-
ment in a 2-year follow-up (Doff et al., 2013). They found that MAD
therapy is associated with increased TMD pain in the first 2 months
of use, but that this TMD side-effect had a transient nature: They
found no difference in TMD pain between the MAD group and their
CPAP group after 1 year. Therefore, they concluded from their study
that, because of the transient nature of TMD pain, this pain is not a
reason to contra-indicate an MAD treatment. Also, Knappe, Bakke,
Svanholt, Petersson, and Sonnesen (2017)) reported a low prevalence
rate of jaw-muscle tenderness, namely, 7.1%, and no significant
changes in orofacial function in association with MAD therapy after
6 months. In our study, TMD pain in the MAD group was also evalu-
ated after 6 months. We hypothesize, based on the outcomes of the
studies of Perez et al. (2013), Doff et al. (2013), and Knappe
et al. (2017), that the TMD pain in our MAD group had already dis-
appeared in the first few months. Therefore, no difference in clinical
signs of TMD pain between the MAD, nCPAP, and placebo groups
was found in our study.
In conclusion, our study showed a low frequency of clinical signs
of TMD pain in mild to severe OSA patients after 6 months, regardless
of treatment with MAD or nCPAP. In addition, no difference in man-
dibular function impairment was observed between the different
treatment modalities.
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